These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 11336617

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE, Matthews DR.
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [Abstract] [Full Text] [Related]

  • 9. [Glimepiride (Amaryl): a review of its pharmacological and clinical profile].
    Bando K, Yamada Y.
    Nihon Yakurigaku Zasshi; 2001 Jul; 118(1):59-67. PubMed ID: 11496829
    [Abstract] [Full Text] [Related]

  • 10. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
    Korytkowski MT.
    Pharmacotherapy; 2004 May; 24(5):606-20. PubMed ID: 15162895
    [Abstract] [Full Text] [Related]

  • 11. [Glimepiride--an oral antidiabetic agent].
    Becić F, Kapić E, Becić E.
    Med Arh; 2003 May; 57(2):125-7. PubMed ID: 12822388
    [Abstract] [Full Text] [Related]

  • 12. The role of glimepiride in the treatment of type 2 diabetes mellitus.
    Briscoe VJ, Griffith ML, Davis SN.
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):225-35. PubMed ID: 20055691
    [Abstract] [Full Text] [Related]

  • 13. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
    Müller G, Hartz D, Pünter J, Okonomopulos R, Kramer W.
    Biochim Biophys Acta; 1994 May 11; 1191(2):267-77. PubMed ID: 8172912
    [Abstract] [Full Text] [Related]

  • 14. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Huang HK, Yeh JI.
    Diabetes Res Clin Pract; 2019 Jun 11; 152():103-110. PubMed ID: 31108137
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone plus glimepiride: a promising alternative in metabolic control.
    Derosa G.
    Int J Clin Pract Suppl; 2007 Jun 11; (153):28-36. PubMed ID: 17594391
    [Abstract] [Full Text] [Related]

  • 16. Clinical profile of glimepiride.
    Draeger E.
    Diabetes Res Clin Pract; 1995 Aug 11; 28 Suppl():S139-46. PubMed ID: 8529506
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.